Drugs / ICAR19 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03383952 | Mar 2017 → Dec 2020 | lymphoid leukemia, lymphoma | Immune Cell, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICAR19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03383952 ↗ |
| Action | Deplete | “can specifically kill CD19+ tumor cells” NCT03383952 ↗ |
| Modality | Cell therapy | “autologous ICAR19 CAR-T cells” NCT03383952 ↗ |
| Route | Intravenous | “infused into the patients by IV” NCT03383952 ↗ |
| Target | CD19 | “anti-CD19 antibody scFV” NCT03383952 ↗ |